B. Wilhelm

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017, PloS one.

Main results of the First-In Human single ascending dose phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2) in glaucoma filtration surgery

H. Thieme, N. Pfeiffer, K. Lorenz, 2017 .

First-inhuman phase I study of ISTH 0036 , an antisense oligonucleotide selectively targeting transforming growth factor beta 2 ( TGF-β 2 ) , in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017 .

Clinical Protocols for the Evaluation of Rod Function

E. Zrenner, K. Bartz-Schmidt, K. Stingl, 2020, Ophthalmologica.

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab† (POLARIS)

J. Sahel, S. Sivaprasad, B. Lorenz, 2018, Acta ophthalmologica.

XOLARIS: A 24-Month, Prospective, Natural History Study of 201 Participants With RPGR-associated X-Linked Retinitis Pigmentosa

J. Duncan, T. Peters, Aaron Nagiel, 2024, Ophthalmology Science.